Legend Biotech (LEGN) Q4 2025 earnings review
CARVYKTI Scale-Up Drives Adjusted Profitability Despite FX Headwinds
Legend Biotech delivered a landmark quarter, with total revenue accelerating 64% YoY to $306.3 million, fueled by CARVYKTI net trade sales hitting $555 million. The completion of the Raritan facility expansion successfully unlocked manufacturing constraints, pushing the CARVYKTI franchise into full-year profitability. While GAAP net income reversed to a $30.9 million loss due to severe EUR/USD macro currency fluctuations, core operations showed immense operating leverage, driving Adjusted Net Income to a positive $2.5 million for the first time.
🐂 Bull Case
The completion of the Raritan expansion positions Legend with the largest US cell therapy manufacturing site, supporting up to 10,000 patients annually. This physically enables the revenue acceleration seen in H2 2025.
The core business has crossed the breakeven threshold. Adjusted net income reached $2.5M in Q4 (up from a $59M loss a year ago), validating management's timeline to company-wide operating profit in 2026.
🐻 Bear Case
Legend's heavy exposure to EUR/USD exchange rates through intercompany loans and cash deposits swung the bottom line by over $57M YoY, forcing a GAAP net loss and obscuring operational progress.
Selling and distribution expenses accelerated 31% YoY to $64.2 million, as the company spends heavily on sales force expansion and market access to drive community setting adoption.
⚖️ Verdict: 🟢
Bullish. The overarching story for Legend was always manufacturing capacity. With supply unblocked, CARVYKTI's unmatched efficacy is translating cleanly into exponential revenue growth and core operating leverage, overshadowing non-cash FX noise.
Key Themes
Manufacturing Capacity Unlocked
A massive historical overhang has been cleared. Legend successfully completed the expansion of its Raritan facility, making it the largest cell therapy manufacturing site in the U.S. Capable of treating up to 10,000 patients annually alongside the Tech Lane and Novartis CMO nodes, supply is no longer the limiting factor for CARVYKTI's growth.
Commercial Dominance in Earlier Lines
CARVYKTI continues to accelerate, with Q4 net trade sales of $555M bringing the FY25 total to $1.9B. The therapy has now treated over 10,000 patients globally. The expansion to 294 sites worldwide and deeper penetration into U.S. community and outpatient settings are paying immense dividends.
Rapid Operating Leverage Improvement
Accelerating. Higher gross profit from CARVYKTI is cascading down the P&L. Operating loss shrank dramatically from $79.3M in 24Q4 to just $19.7M in 25Q4. With R&D expenses stabilizing ($101.3M in Q4 vs $104.4M a year ago), revenue growth is successfully translating into margin improvement.
Macro Picture: Heavy FX Exposure Distorting GAAP Execution
Reversing. While Adjusted Net Income was positive, GAAP Net Income swung to a $30.9M loss (from a $26.4M profit in 24Q4). Management attributed the $57.3M year-over-year change primarily to macro exposure—specifically unrealized foreign currency exchange losses on intercompany loans and cash due to EUR/USD fluctuations. This introduces significant reporting volatility.
GAAP Losses Contradict Franchise Profitability Narrative
While management touted 'CARVYKTI franchise profitability,' total company financials remain in the red on an unadjusted basis. Selling and distribution expenses accelerated 31% YoY to $64.2 million. This specific data point contradicts the pure profitability narrative, highlighting that capturing community market share remains highly capital intensive.
Pipeline Advancement: Next-Generation Innovation
Legend is moving aggressively beyond standard autologous therapies. The company opened a 31,000-square-foot R&D facility in Philadelphia, dosed the first patient for its novel in vivo pipeline candidates, and presented encouraging first-in-human results for LUCAR-G39D, an allogeneic (off-the-shelf) CAR-T candidate targeting B-cell non-Hodgkin lymphoma.
Other KPIs
Stable/Decelerating. R&D spending decreased slightly from $104.4M in 24Q4. The reduction in late-stage BCMA clinical program expenditures is funding higher pipeline-related R&D activities without expanding the overall cost envelope.
Stable. The balance sheet remains heavily fortified, down slightly from ~$1.1B at the end of 2024, but providing ample runway to cross the 2026 profitability threshold without the need for dilutive capital raises.
Accelerating. Up 65% YoY from $168.0 million, directly reflecting Legend's 50% share of U.S. and 30% share of Greater China profits from the soaring sales of CARVYKTI under the Janssen agreement.
Guidance
Management explicitly reiterated their belief that Legend Biotech will achieve a company-wide operating profit in 2026 (excluding unrealized foreign exchange fluctuations). With Q4 2025 operating loss narrowing to just $19.7M, achieving this threshold appears highly probable.
Key Questions
Community Setting Unit Economics
Selling and distribution expenses grew over 30% this quarter. As the mix shifts further toward community and regional settings, what is the steady-state expectation for SG&A as a percentage of revenue?
Managing FX Volatility
Given the severity of the EUR/USD fluctuations masking the underlying operational progress this quarter, are there plans to implement active currency hedging strategies to stabilize reported net income?
10,000 Dose Capacity Utilization
With the Raritan expansion complete and the 10,000 annualized dose capacity largely online, what is the expected utilization rate of this capacity in H1 2026, and are demand constraints (e.g. bed space) becoming the new bottleneck?
In Vivo and Allogeneic Strategy
With the first in vivo patients dosed and LUCAR-G39D data presented, how should investors think about the timeline and capital allocation required to move these next-generation therapies into pivotal stages?